Biosimilar User Fee Agreement Allows For Reliance On Foreign Clinical Data, FDAer Says
This article was originally published in The Pink Sheet Daily
Agency interactions with sponsors under BsUFA are not dependent upon opening an IND. Sponsors may be able to demonstrate similarity to an FDA-licensed reference product by bridging to foreign clinical data, Associate Director for Biosimilars Leah Christl says.
You may also be interested in...
Sandoz’s Biosimilar Data-Bridging Plans For Zarxio Faced FDA Doubts
FDA 'strongly encouraged' Sandoz to conduct three-way clinical PK/PD study comparing its Zarxio biosimilar to the EU- and U.S.-approved versions of Amgen’s Neupogen; however, the firm succeeded in using only analytical data to justify relevance of studies using the European reference product.
FDA Sets Biosimilar Application Fees, But Is Silent On Volume Projections
A Federal Register notice outlines the new user fee amounts and suggests that President Obama’s budget projections anticipated as many as 10 marketing applications, but the mix of INDs and full applications is unknown.
Biosimilar Guidance Comments Reveal Small Window Of Agreement On Foreign Data
In comments on FDA’s three biosimilar draft guidances, PhRMA and BIO seek a more limited role in biosimilar approval decisions for clinical data involving foreign reference products than does GPhA, but all the trade associations believe that the foreign product needs to be made by the same company in the same facility as the U.S.-licensed reference product.